Project Grant R43CA297808
Award Date
12/1/24
Completion Date
11/30/25
Dollars Obligated
$357K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
New York, NY 10023, USA
Similar Awards
This Cooperative Agreement award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will fund the development of an integrated platform to bridge bioinformatics and mathematical modeling for patient-specific mechanistic tumor modeling. The $811,500 award to the Trustees of Indiana University, effective September 1, 2024, will refine existing software like COGAPS, ProjectR, SpaceMarkers, and DOMINO to analyze single-cell and spatial multi-omics data and learn...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of novel human-relevant lung adenocarcinoma models. The $160,330 award, effective December 1, 2024 through November 30, 2026, aims to:
Introduce oncogenic mutations into primary human lung stem and progenitor cells to generate organoid models for high-throughput drug testing.
Xenograft the mutated stem/progenitor cells into immunodeficient mouse lungs to develop an...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to evaluate the congruence and selection of cancer models, such as cell lines, patient-derived xenografts, and organoids, towards enabling precision cancer research and translational applications. The $585,931 grant will fund a 5-year project that aims to: 1) identify and clinically annotate prevalent subclones and tumor microenvironment cell types in breast cancer, 2)...
The National Cancer Institute (NCI) awarded a $766,773 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Dana-Farber Cancer Institute, Inc. (DFCI) for the project "Inclusion of Diverse and Medically Underserved Populations in the Design and Implementation of the PREMMPLUS Patient-Facing App." The grant aims to evaluate a patient-facing mobile app version of the PREMMPLUS multigene cancer risk assessment model in diverse community health...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $398,895 to Keliomics, Inc. to develop breakthrough models of breast cancer for use in therapeutic development. The key products and services to be delivered include:
Identifying the specific conditions to generate models of Black breast cancer, White breast cancer, early breast cancer, and advanced breast cancer using Keliomics' patented technology that can keep human breast...
The National Cancer Institute (NCI) awarded a $621,732 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Medical University of South Carolina (MUSC). The 5-year grant, awarded on August 1, 2024, will fund research to comprehensively assess the effectiveness of a proactive identification and digital mental health intervention approach to address unmet psychosocial needs of individuals living with likely incurable cancer. The project aims to develop an...
The National Cancer Institute (NCI) awarded a $1,217,906 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Cosmyc Inc. of Dover, DE. The grant, with a funding period from June 18, 2024 to May 31, 2025, will support research into the therapeutic inhibition of the MYC:TRRAP interaction in cancer. This fundamental cancer biology research aims to provide critical insights into the molecular and cellular mechanisms underlying cancer development and progression, with the...
This $544,475 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development and validation of a novel in vitro cancer metastasis model system using decellularized organ tissues, or "biomatrices." The primary objectives are to:
Generate a comprehensive panel of biomatrices representing common sites of cancer metastasis (e.g. liver, lung) to recapitulate organ-specific tumor biology and treatment response.
Demonstrate the...
The National Cancer Institute (NCI) awarded a $432,304 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Trustees of Columbia University in the City of New York, Health Sciences Division, to develop enhanced cancer risk prediction models for underrepresented Black and Hispanic populations. The 5-year project, beginning January 3, 2025, aims to create novel data integration methods that effectively leverage diverse data sources, including electronic...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $627,833 Project Grant to The University of Texas Southwestern Medical Center to develop an informatics platform that integrates molecular and pathology data from various lung cancer preclinical models and patient tumors. The goal is to establish a cross-comparison platform to assess the fidelity of preclinical lung cancer models in relation to human tumors.
The project has three specific aims: 1) Harmonize...